What is the mechanism of action of finasteride in treating benign prostatic hyperplasia (BPH)?

Finasteride functions by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), which is a potent androgen that plays a crucial role in the development and enlargement of the prostate gland. In cases of benign prostatic hyperplasia (BPH), elevated levels of DHT can lead to an enlarged prostate, resulting in urinary obstruction and related symptoms. By reducing the levels of DHT, finasteride effectively decreases prostate volume and alleviates urinary symptoms associated with BPH.

This mechanism of action is vital for the management of BPH, as it not only helps to minimize the mass of prostate tissue but also addresses the root cause linked to hormone action within the prostate gland. As a result, finasteride can lead to improved urinary flow and decreased incidence of urinary retention, enhancing the overall quality of life for patients dealing with this condition.